Book Value per Share: Lucid Diagnostics, Inc. (LUCD)

Graphic logo of Lucid Diagnostics, Inc. (LUCD)

Lucid Diagnostics Inc. (LUCD) leads the development of the EsoGuard AI test for detecting gastrointestinal oncology via DNA markers. This chart on GURU.Markets reflects a value of 0.06. The business focuses on creating a diagnostic environment by integrating non-invasive screenings into standard examinations. The company's stability is underpinned by the humanitarian status of medicine, rendering its growth in the US independent of global political tensions.

Lucid Diagnostics, Inc. (LUCD) - Accounting Value per Share from 07/04/2022 to 10/27/2026

Summary analytical data breakdowns for luciddx.com (LUCD)

- price and consensus price forecast:
Stock Price Lucid Diagnostics Inc|LUCD - Consensus Target
- market capitalization data:
Market Capitalization Lucid Diagnostics Inc.|LUCD - Business Value
- book capitalization data:
Net Assets per Single Share Lucid Diagnostics|LUCD - Company Net Assets|Market Capitalization to Book Value Ratio luciddx.com|LUCD - Company Assets
- debt and liquidity data:
Total Debt to Capital Lucid Diagnostics Inc.|LUCD - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Lucid Diagnostics|LUCD - Company Aggregate Debts|Debt to Book Capitalization Ratio Lucid Diagnostics Inc.
Fundamental company valuation:Lucid Diagnostics Inc.
Manufactured product of luciddx.com

Book value per share reflects the company's net equity distributed across a single common share, allowing for an assessment of the actual value of assets minus liabilities. By analyzing the book value per common share trend, an investor determines the fundamental stability of Lucid Diagnostics Inc. (LUCD), which is critical when scaling commercial EsoGuard testing and expanding insurance coverage.

Competitors of Lucid Diagnostics Inc. (LUCD)

A: Book Value per Share|DGX - Accounting Value per Share|Book Value per Share Illumina, Inc.|EXAS (exactsciences.com) - Equity per Share|Net Assets per Single Share RVTY|Accounting Value per Share Bio-Rad Laboratories, Inc.|Anbio Tech - Book Value per Share|Net Asset Value per Share Nordion (SHC)|QDEL - Book Value per Share|Equity per Share opko.com OPK|CareDx, Inc - Book Value per Share|MRVI: Book Value per Share|Net Assets per Single Share Fulgent Corp|Standard BioTools Corp (LAB) - Equity per Share|CTKB (Cytek Biosciences, Inc.) - Book Value per Share|Book Value per Share OSUR|Net Assets per Single Share Exagen Inc. (XGN)|Net Assets per Single Share MDxHealth S.A. MDXH|PRE: Accounting Value per Share|Insight Molecular Diagnostics, Inc. - Net Asset Value per Share|Net Assets per Single Share TRIB (Trinity Biotech Corp)|PRPH - Net Assets per Share|Ainos - Book Value per Share|CODX (Co-Diagnostics Inc) - Net Assets per Share|HSCS: Net Assets per Single Share|Net Assets per Share BMRA|Net Assets per Single Share Cardio Diagnostics (CDIO)|Net Assets per Single Share viraxbiolabs.com VRAX|Accounting Value per Share BJDX (Bluejay Diagnostics, Inc.)|Book Value per Share Aspira Women's Health, Inc. AWH|AXDX: Book Value per Share|CNTG - Accounting Value per Share|enzo.com - Book Value per Share|Fresh2 Group (FRES) - Net Assets per Share|Book Value per Share Genetic Technologies Ltd (GENE)|Equity per Share 23andMe Holding Co (ME)|Psychemedics Corp (PMD) - Accounting Value per Share